Balyasny Asset Management LLC Cure Vac N.V. Transaction History

Balyasny Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.96 - $6.41 $189,398 - $306,577	-47,828 Reduced 64.51%	26,317 $110,000
Q3 2023 Nov 14, 2023	SELL	$6.5 - $10.77 $3.58 Million - $5.93 Million	-550,733 Reduced 88.13%	74,145 $506,000
Q2 2023 Aug 14, 2023	SELL	$6.69 - $12.25 $3.28 Million - $6.01 Million	-490,885 Reduced 44.0%	624,878 $6.51 Million
Q1 2023 May 15, 2023	SELL	$6.38 - $12.5 $1.82 Million - $3.56 Million	-284,532 Reduced 20.32%	1,115,763 $7.78 Million
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $8.05 Million - $11.9 Million	1,400,295 New	1,400,295 $8.44 Million
Q2 2022 Aug 15, 2022	SELL	$13.18 - $19.41 $2.48 Million - $3.65 Million	-187,858 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $2.77 Million - $6.62 Million	187,858 New	187,858 $3.68 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $514M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.